Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isolated Hepatic Perfusion With Melphalan for Unresectable Liver Cancers
NCT00019786Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Aug 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan in liver cancer and liver metastasis, sponsored by National Institutes of Health. Primary endpoints: Response rate, Duration of response and 3 more. Started Aug 1999; status: completed.
02
Drugs
melphalan
03
Conditions
liver cancerliver metastasis
Beyond the preview
Go deeper on NCT00019786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019786.